Skip to main content

Isomorphic Labs Secures $5 Billion to Advance Drug Candidates to Clinical Trials

Isomorphic Labs, an AI-driven drug-discovery platform established in 2021 following its separation from Google DeepMind, has successfully secured $5 b

1 min read6 views5 tags
Originally reported bytechcrunch

Isomorphic Labs, an AI-driven drug-discovery platform established in 2021 following its separation from Google DeepMind, has successfully secured $5 billion in a Series C funding round with the goal of advancing its drug candidates into clinical trials.

This funding round was jointly led by Greenoaks and Sequoia Capital, with new participation from Andreessen Horowitz and various other investors. Additionally, all existing backers, including Alphabet’s venture arms GV and Capital G, Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund, increased their investments.

Isomorphic Labs has developed an AI drug-design engine that utilizes a suite of simulation models to explore different chemical domains, facilitating the design of new therapeutics. Building upon DeepMind’s pioneering AlphaFold protein-folding model, the company reports positive preclinical results in oncology and immunology. As a result, the enterprise has established partnerships with major pharmaceutical companies such as Eli Lilly, Novartis, and Johnson & Johnson.

This latest capital injection, following a $2.1 billion Series B round in May, is intended to support the continuous development of its drug-design engine and to expand into a broader range of medical fields.

This Series C round marks the company's initial fundraising since its founder and CEO, Demis Hassabis, stepped down as DeepMind’s head to dedicate himself entirely to drug discovery, a transition that also saw him assume the role of chairman at DeepMind. Hassabis and former DeepMind director John Jumper were awarded the Nobel Prize in Chemistry for their work on AlphaFold, a revolutionary system capable of predicting a protein’s three-dimensional structure using only its genetic sequence.

Isomorphic Labs has not disclosed its latest valuation, though Bloomberg reported earlier this month that the organization was seeking to raise funds at a $50 billion valuation.

#AI News#Isomorphic Labs#AlphaFold#Drug Discovery#Clinical Trials
ES
Editorial StaffEditor

The Editorial Staff at AIChief is a team of professional content writers with extensive experience in AI and marketing. Founded in 2025, AIChief has quickly grown into the largest free AI resource hub in the industry.

View all posts
Reader feedback

What did you think of this story?

User Comments

Filter:
No comments yet. Be the first to comment!
Continue reading
View all news